London’s Spex Capital, a leading early-stage investor tackling global healthcare challenges through HealthTech solutions, today announced the first €30 million commitment to its flagship €100 million Venture HealthTech Fund.
The fund will invest globally in early-stage HealthTech startups, from Seed to Series A/B, with investments of up to €5 million.
Spex has partnered with EIT Digital and Penn Medicine/LGH, a leading mutli-hospital health system in the US that handles over 7 million patients each year.
Claudio D’Angelo, Founder and CEO of Spex Capital, said: “Healthcare faces immense challenges worldwide with ageing populations creating growing patient demand and systemic cost pressures. Our true strength is not just the volume of companies we see, but the unparalleled power of our distribution network to provide them with essential commercial and clinical validation.”
Several other funds have also entered or expanded within the European healthtech investment space in 2025, indicating sustained investor appetite for early-stage digital health and medical innovation.
London-based Meridian Health Ventures launched a €44.7 million transatlantic fund to back HealthTech startups scaling between the UK and the United States. Belgium’s Capricorn Partners announced a €51 million first close for its Health-Tech Fund II, targeting diagnostics, digital health, and life-science ventures. In France, M2care secured €26 million to accelerate venture studio activity in healthcare innovation.
Against this backdrop, Spex Capital’s €100 million Venture HealthTech Fund sits among the largest of the current European initiatives focused on early-stage health technology, highlighting growing institutional confidence in the sector’s potential.
Its partnerships with EIT Digital, Penn Medicine, and long-standing links to the NHS provide access to extensive validation networks, a factor often cited as a bottleneck in scaling health technologies.
In a year where European healthtech investment surpassed €4 billion in early 2025, according to EU-Startups’ sector overview, Spex Capital’s entry signals sustained investor confidence in digital health and medical innovation.
“The supply is strong, but the validation we deliver through our network is the game-changer. Digital HealthTech is key to addressing these challenges, and with this fund, our new partnerships, and a world-class advisory network, we are uniquely positioned to support visionary founders delivering transformative solutions worldwide,” added D’Angelo.
Founded in 2021 by serial entrepreneur Claudio D’Angelo, Spex Capital focuses on commercialising and scaling digital health and medical technology solutions across major healthcare delivery systems worldwide.
The company also announced the appointment of Lord Markham, former UK Health Minister, as Chair of the Board. He has extensive experience across the public, private and voluntary sectors, particularly in the venture space where he co-founded a HealthTech business, Cignpost, which grew from €0 to €350 million turnover in 1 year.
Lord Markham, Chairman, said: ”I’m delighted to join Spex Capital at such a pivotal moment for HealthTech. This scale-up fund will unleash groundbreaking startups. I look forward to working with Claudio and the team as we accelerate the development and adoption of technologies that improve patient outcomes and reshape healthcare delivery globally. “
EU-Startups previously covered the firm in February 2023, when Spex Capital first announced plans for its €100 million HealthTech fund.
Read the orginal article: https://www.eu-startups.com/2025/10/british-healthtech-investor-spex-capital-announces-e30-million-commitment-to-e100-million-fund/
